CDK4/6抑制剂联合mTOR抑制剂在乳腺癌中的作用机制

doi:10.11904/j.issn.1002-3070.2019.05.018

Abstract

Abstract: Many studies indicate that the CDK-RB-E2F pathway and the PI3K-AKT-mTOR pathway play key roles in the mechanism of drug resistance in breast cancer.Through studies of two pathways,the combination of CDK4/6 inhibitors and endocrine drugs can improve the survival rate of patients with hormone receptor-positive breast cancer,and mTOR inhibitors also show the anti-tumor strength.Recent studies have shown that the combination of mTOR inhibitors and CDK4/6 inhibitors can further inhibit the activation of the CDK-RB-E2F pathway and synergistically controls tumor cell proliferation.It was also found that the CDK-RB-E2F pathway in CDK4/6 inhibitor-resistant patients was reactivated and sensitive to mTOR inhibitor.Other studies have also shown that CDK4/6 inhibitors and mTOR inhibitors can synergistically control tumorigenesis through autophagy.This article reviews several mechanisms of combination of two drugs.

Key words: CDK4/6 inhibitors, mTOR inhibitors, E2F, RB, Breast cancer, Autophagy

CLC Number:

R737.9

LIU Eryu, YANG Hao, LIANG Guohua, ZHAO Yanfang, ZHAO Wenhui. Action for CDK4/6 inhibitors combined with mTOR inhibitors in breast cancer and its mechanism[J]. Journal of Practical Oncology, 2019, 33(5): 476-480.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2019.05.018

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2019/V33/I5/476

References

1 Coates AS,Winer EP,Goldhirsch A,et al.Tailoring therapies-improving the management of early breast cancer:St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J].Ann Oncol,2015,26(8):1533-1546.
2 Early Breast Cancer Trialists′ Collaborative Group.Aromatase inhibitors versus tamoxifen in early breast cancer:patient-level meta-analysis of the randomised trials[J].Lance,2015,386(10001):1341-1352.
3 Wilson S,Chia SK.Treatment algorithms for hormone receptorpositive advanced breast cancer:applying the results from recent clinical trials into daily practice-insights,limitations,and moving forward[J].Am Soc Clin Oncol Educ Book,2013,2013:20-27.
4 Tripathy D.The BMC medicine breast cancer collection:an illustration of contemporary research and clinical care[J].BMC Medicine,2015,13:223.
5 Bevers TB,Helvie M,Bonaccio E,et al.Breast cancer screening and diagnosis,version 3.2018,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2018,16(11):1362-1389.
6 Laplante M,Sabatini DM.mTOR signaling in growth control and disease[J].Cell,2012,149(2):274-293.
7 Yip CK,Murata K,Walz T,et al.Structure of the human mTOR complex I and its implications for rapamycin inhibition[J].Molecular Cell,2010,38(5):768-774.
8 Pardee AB.A Restriction point for control of normal animal cell proliferation[J].Proc Natl Acad Sci U S A,1974,71(4):1286-1290.
9 Chumsri S,Sabnis G,Tkaczuk K,et al.mTOR inhibitors:changing landscape of endocrine-resistant breast cancer[J].Future Oncol,2014,10(3):443-456.
10 Baselga J,Campone M,Piccart M,et al.Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J].N Engl J Med,2012,366(6):520-529.
11 Hortobagyi GN,Chen D,Piccart M,et al.Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:results from BOLERO-2[J].J Clin Oncol,2016,34(5):419-426.
12 Yardley DA,Noguchi S,Pritchard KI,et al.Everolimus plus exemestane in postmenopausal patients with HR+Breast Cancer:BOLERO-2 final progression-free survival analysis[J].Adv Ther,2013,30(10):870-884.
13 Michaloglou C,Crafter C,Sierbaek R,et al.Combined inhibition of mTOR and CDK4/6 Is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer[J].Mol Cancer Ther,2018,17(5),908-920.
14 Hortobagyi GN,Stemmer SM,Burris HA,et al.Updated results from MONALEESA-2,a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive,HER2-negative advanced breast cancer[J].Ann Oncol,2018,29(7):1541-1547.
15 Guichard SM,Curwen J,Bihani T,et al.AZD2014,an inhibitor of mTORC1 and mTORC2,Is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules[J].Mol Cancer Ther,2015,14(11):2508-2518.
16 Finn RS,Martin M,Rugo HS,et al.Palbociclib and Letrozole in advanced breast cancer[J].N Engl J Med,2016,375(20):1925-1936.
17 Thurlings I,de Bruin A.E2F transcription factors control the roller coaster ride of cell cycle gene expression[J].Methods Mol Biol,2016,1342:71-88.
18 Zhang J,Xu K,Liu P,et al.Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of Akt[J].Mol Cell,2016,62(6):929-942.
19 Bonelli MA,Digiacomo G,Fumarola C,et al.Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells[J].Neoplasia,2017,19(8):637-648.
20 Perez-Mancera PA,Young AR,Narita M.Inside and out:the activities of senescence in cancer[J].Nat Rev Cancer,2014,14(8):547-558.
21 Otto T,Sicinski P.Cell cycle proteins as promising targets in cancer therapy[J].Nat Rev Cancer,2017,17(2):93-115.
22 Debacq-Chainiaux F,Erusalimsky JD,Campisi J,et al.Protocols to detect senescence-associated beta-galactosidase(SA-betagal)activity,a biomarker of senescent cells in culture and in vivo[J].Nat Protoc,2009,4(12):1798-1806.
23 Tomimatsu K,Narita M.Translating the effects of mTOR on secretory senescence[J].Nat Cell Biol,2015,17(10):1230-1232.
24 Wang W,Dong L,Saville B,et al.Transcriptional activation ofE2F1gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions[J].Mol Endocrinol,1999,13(8):1373-1387.
25 Bahri A,Li Z,Morel JM,et al.PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer[J].Sci Transl Med,2015,7(283):283ra51.
26 Alayev A,Salamon RS,Berger SM,et al.mTORC1 directly phosphorylates and activates ERa upon estrogen stimulation[J].Oncogene,2015,35:3535-3543.
27 Yamnik RL,Digilova A,Davis DC,et al.S6 Kinase 1 regulates estrogen receptor in control of breast cancer cell proliferation[J].J Biol Chem,2009,284(10):6361-6369.
28 Herrera-Abreu MT,Palafox M,Asghar U,et al.Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer[J].Cancer Res,2016,76(8):2301-2313.
29 Sherr CJ,Beach D,Shapiro GI.Targeting CDK4 and CDK6:from discovery to therapy[J].Cancer Discovery,2016,6(4):353-367.
30 O′Leary B,Finn RS,Turner NC.Treating cancer with selective CDK4/6 inhibitors[J].Nature Reviews Clinical Oncology,2016,13(7):417-430.
31 Johnson J,Thijssen B,McDermott U,et al.Targeting the RB-E2F pathway in breast cancer[J].Oncogene,2016,35(37):4829-4835.
32 Yang C,Li Z,Bhatt T,et al.Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence[J].Oncogene,2017,36(16):2255-2264.
33 Jansen VM,Bhola NE,Bauer JA,et al.Kinome-Wide RNA interference screen revealsa role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer[J].Cancer Res,2017,77(9):2488-2499.
34 Knudsen ES,Witkiewicz AK.The strange case of CDK4/6 inhibitors:mechanisms,resistance,and combination strategies[J].Trends Cancer,2017,3(1):39-55.
35 Yang Z,Klionsky DJ.Eaten alive:a history of macroautophagy[J].Nature Cell Biology,2010,12(9):814-822.
36 Yoshida GJ.Metabolic reprogramming:the emerging concept and associated therapeutic strategies[J].J Exp Clin Cancer Res,2015,34(1):1-10.
37 Fan Y,Dickman KG,Zong WX.Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition[J].J Biol Chem,2010,285(10):7324-7333.
38 Fritz V,Fajas L.Metabolism and proliferation share common regulatory pathways in cancer cells[J].Oncogene,2010,29(31):4369-4377.
39 Fajas L.Re-thinking cell cycle regulators:the cross-talk with metabolism[J].Front Oncol,2013,3(3):4.
40 Olmez I,Brenneman B,Xiao A,et al.Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms[J].Clin Cancer Res,2017,23(22):6958-6968.
41 Deberardinis RJ,Lum JJ,Hatzivassiliou G,et al.The biology of cancer:metabolic reprogramming fuels cell growth and proliferation[J].Cell Metab,2008,7(1):11-20.
42 Sonia Pernas,Sara M,Tolaney,et al.CDK4/6 inhibition in breast cancer:current practice and future directions[J].Ther Adv Med Oncol,2018,10:1758835918786451.

[1]	SHI Manru, E Mingyan. Effect of delayed radiotherapy on the prognosis of patients with different molecular subtypes of breast cancer [J]. Journal of Practical Oncology, 2019, 33(5): 431-435.
[2]	LI Lei, ZHANG Qingyuan. Clinical progress of anti-tumor vascular therapy for breast cancer [J]. Journal of Practical Oncology, 2019, 33(5): 461-465.
[3]	WANG Yu, QIAO Juanjuan, ZHANG Lei, LIU Siwei, YANG Shucai. The role of steroid hormones in breast cancer and its effect on cancer stem cells [J]. Journal of Practical Oncology, 2019, 33(5): 466-470.
[4]	AN Weiwei, TANG Yali, ZHAO Lianhua, YANG Yue, WANG Xinling. Polyphenylene-polysaccharide complex from pinus koraiensis extract induces apoptosis in human breast cancer MCF-7 cells [J]. Journal of Practical Oncology, 2019, 33(4): 289-293.
[5]	HU Lin, SHEN Jia. Growth differentiation factor 15 plays a role in predicting and monitoring the cardiotoxicity of epirubicin/cyclophosphamide-docetaxel-trastuzumab in the treatment of patients with HER-2 positive breast cancer [J]. Journal of Practical Oncology, 2019, 33(4): 340-345.
[6]	MA Yan, HE Hong, WANG Sainan. Clinical study of docetaxel in the treatment of metastatic breast cancer in different age groups [J]. Journal of Practical Oncology, 2019, 33(4): 352-356.
[7]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[8]	LI Shuo,ZHANG Nannan,LI Liangliang,LONG Zhiping,YIN Huihui,ZHAO Yashuang,WANG Fan. Relationship between PDE4C gene methylation in peripheral blood leukocytes,interaction of environmental factors and pathogenesis of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 233-238.
[9]	CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.
[10]	SUN Jianghong, HAO Mingzhu, JIANG Dan, GUO Fei, LI Xiaomei. FFDM differential diagnosis of mastitis,benign hyperplasia and breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 139-141.
[11]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[12]	MA Zhingying, SHANG Naijian, CAI Miaotian, SHEN Yang, JIANG Zhiyun. Correlation between HER-2 receptor of progesterone and estrogen receptor-positive breast cancer and mammography imaging & clinicopathological features [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 47-51.
[13]	LI Cheng, LAN Li, YANG Chao, ZHANG Tingting, WANG Rui, LIN Lin, TIAN Wenjing. Analysis of the incidence and mortality of malignant tumors in Harbin from 2015 to 2017 [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 62-66.
[14]	BIAN Xiusen, LI Guang, GUAN Xinyu, ZHANG Yi, DI Chang, MA Can. Molecular mechanism of UHRF1 inhibiting proliferation of lung adenocarcinoma cells by regulating autophagy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 498-502.
[15]	HE Xu, YE shangmian, DONG dandan, LI Ke. The expression of HLA-G in breast cancer and its significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 410-414.

Action for CDK4/6 inhibitors combined with mTOR inhibitors in breast cancer and its mechanism

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments